Analyst Ratings For Abcam (LON:ABC)
Today, Berenberg Bank lowered its price target on Abcam (LON:ABC) to GBX 1,330 per share.
There are 2 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Abcam (LON:ABC) is Buy with a consensus target price of GBX 1,333.33 per share, a potential .
Some recent analyst ratings include
- 3/12/2019-Abcam (LON:ABC) had its Buy rating reiterated by Peel Hunt
- 1/10/2019-Abcam (LON:ABC) had its Neutral rating reiterated by JPMorgan Chase & Co.
- 9/11/2017-Abcam (LON:ABC) had its Sell rating reiterated by Panmure Gordon
- 5/2/2017-Abcam (LON:ABC) had its Hold rating reiterated by Stifel Nicolaus with a GBX 890 price target
About Abcam (LON:ABC)
Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays. Its products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company also sells its products online. Abcam plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Recent Trading Activity for Abcam (LON:ABC)
Shares of Abcam closed the previous trading session at 079,00 −18,00 1,64 % with 78.67 shares trading hands.
